Premium
NO • /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer
Author(s) -
Wang Limin,
Tang Wei,
Yang Shouhui,
He Peijun,
Wang Jian,
Gaedcke Jochen,
Ströbel Philipp,
Azizian Azadeh,
Ried Thomas,
Gaida Matthias M.,
Yfantis Harris G.,
Lee Dong H.,
Lal Ashish,
Van den Eynde Benoit J.,
Alexander H. Richard,
Ghadimi B. Michael,
Hander,
Hussain S. Perwez
Publication year - 2019
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.32733
Subject(s) - kynurenine , pancreatic cancer , cancer research , aryl hydrocarbon receptor , biology , kynurenine pathway , signal transduction , indoleamine 2,3 dioxygenase , cancer , medicine , transcription factor , microbiology and biotechnology , gene , biochemistry , tryptophan , genetics , amino acid
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy and is refractory to available treatments. Delineating the regulatory mechanisms of metabolic reprogramming, a key event in pancreatic cancer progression, may identify candidate targets with potential therapeutic significance. We hypothesized that inflammatory signaling pathways regulate metabolic adaptations in pancreatic cancer. Metabolic profiling of tumors from PDAC patients with a high‐ (>median, n = 31) and low‐NOS2 (inducible nitric oxide synthase;